CTXR vs. VTGN, DARE, PTI, MACK, ACIU, OCS, KRRO, ERAS, VERV, and ANNX
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Vistagen Therapeutics (VTGN), Daré Bioscience (DARE), Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), AC Immune (ACIU), Oculis (OCS), Korro Bio (KRRO), Erasca (ERAS), Verve Therapeutics (VERV), and Annexon (ANNX). These companies are all part of the "medical" sector.
Citius Pharmaceuticals (NASDAQ:CTXR) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.
In the previous week, Vistagen Therapeutics had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 2 mentions for Vistagen Therapeutics and 1 mentions for Citius Pharmaceuticals. Vistagen Therapeutics' average media sentiment score of 0.77 beat Citius Pharmaceuticals' score of 0.20 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
Citius Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 556.28%. Vistagen Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 401.32%. Given Citius Pharmaceuticals' higher probable upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Vistagen Therapeutics.
Vistagen Therapeutics received 74 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 62.16% of users gave Citius Pharmaceuticals an outperform vote.
Citius Pharmaceuticals has higher earnings, but lower revenue than Vistagen Therapeutics.
16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 15.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Citius Pharmaceuticals has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Citius Pharmaceuticals' return on equity of -40.78% beat Vistagen Therapeutics' return on equity.
Citius Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Summary
Citius Pharmaceuticals and Vistagen Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
